Region Gaevleborg — Clinical Trial Site

40 Registered trials

18 Currently recruiting

Organisation

Region Gaevleborg

Location

Gavle, Sweden

Identifier

ORG-100046930

Address

Rektorsgatan 1, 802 50, Sweden

Departments

Department of Internal Medicine
Department of Oncology
Department of Surgical Sciences; Vascular Surgery
Diabetesmottagningen, Gävle sjukhus, Lasarettvägen 1, 80324, Gävle
Gävle Hospital, Department of Ophatlomolgy. Lasarettsvägen 1, 803 24 Gävle
Gävle Hospital, women´s clinic, Lasarettsvägen 1, 80188 Gävle
Gävle sjukhus Lungenheten
Gävle Sjukhus Njurmottagningen Lasarettväge
Gävle sjukhus, Infektion, Lasarettsvägen 1, 801 88 Gävle
Gävle Sjukhus, Lungenheten
Gävle sjukhus, Neurologmottagningen
Gävle Sjukhus, Onkologiska mottagningen
Gävle Strand Hälsoscentral OCH Valbo Hälsocenter, Norra Skeppsbron 13, 803 10 Gävle
Hematology
Lungenheten
Lungenheten Gävle sjukhus
Lungenheten Lasarettsvägen 1, Gavle sjukhus
Lungmedicin
Lungmottagningen
Medical Sciences
Medicinkliniken, Gävle sjukhus
NA
Njurkliniken (internmedicin)
Oncology
Oncology department
Onkologkliniken, Gävle sjukhus
Onkologmottagningen
Pulmonary department
Region Gävleborg
Reumatologisk klinik, Gävle sjukhus
Sandvikens akademiska vårdcentraler, Sandviken
VO Internmedicin, Lungenheten
VO Kardiologi, Gävle Sjukhus

Clinical trials at this site (40)

Search interface

HiHat trial Pending

2024-519700-28-01 Patients with relapsing-remitting multiple sclerosis wi 4
A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending

2025-524623-50-00 Solid Tumors 9
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 small cell lung cancer 5 2026-06-23
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting

2025-523586-18-00 Non-Small Cell Lung Cancer 5 2026-06-11
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A randomized study in testicular cancer without metastasis, comparing two different types of chemotherapy used to reduce the risk of relapse Recruiting

2024-518399-29-00 Testicular cancer 5 2024-12-27
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl… Recruiting

2023-506998-35-00 Glioblastoma 5 2025-01-08
Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden Recruiting

2024-518857-41-00 HPV infection and related diseases, such as cervical in 6 2024-11-29
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 cutaneous malignant melanoma 5 2024-11-15
Influence of antibiotic treatment on the normal flora and the presence of resistance genes in known carriers of ESBL and VRE Recruiting

2024-517434-17-01 VRE Carriage, ESBL Carriage 6 2024-10-25
SGLT2 inhibitor or metformin as standard treatment in early type 2 diabetes (SMARTEST) Recruiting

2024-516228-33-00 Type 2 Diabetes 6 2024-08-30
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
Alternative antibiotics to multidrug-resistant UTIs Recruiting

2024-513294-41-00 Urinary tract infection and/or bacteremia caused by ext 6 2023-04-17
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study Recruiting

2024-518172-31-01 EGFR-mutated non-small cell lung cancer (NSCLC) not ame 5 2022-06-14
A randomized double-blind clinical trial comparing Hypochlorous Acid and Polyhexamethylene biguanide in treating diabetic foot ulcers Recruiting

2024-512612-22-00 Diabetic Foot Ulcer 5 2021-12-09
OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting

2023-507164-39-00 Induction of labour 6 2021-12-01
Does metformin reduce growth rate of small abdominal aortic aneurysms? Recruiting

2024-517387-37-00 Small abdominal aortic aneurysm (AAA) under active surv 4 2019-12-12
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
HARMONi-3 Ended

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti… Ended

2024-512439-54-01 Non-small cell lung cancer (NSCLC) 4 2024-07-24